Medullary Thyroid Cancer Symptoms: Early Signs, Genetic Testing, and Diagnosis
At a Glance: Medullary Thyroid Cancer Testing
- Sample Required: Blood sample (for calcitonin, CEA, and genetic testing) or fine-needle aspiration biopsy (for cytology)
- Fasting Rules: No fasting required for calcitonin or genetic tests; however, avoid biotin supplements 48 hours prior to blood draw
- Turnaround Time (TAT): 3–5 business days for calcitonin/CEA; 10–14 days for genetic testing (NGS/WES)
- Base Cost: [Insert Current 2026 Price]
Understanding Medullary Thyroid Cancer
Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor arising from parafollicular C cells of the thyroid, which secrete calcitonin. It accounts for 3–4% of all thyroid cancers but is responsible for a disproportionate number of thyroid cancer–related deaths. MTC occurs in two forms: sporadic (75%) and hereditary (25%) as part of multiple endocrine neoplasia type 2 (MEN2) syndromes. Hereditary MTC is caused by germline mutations in the RET proto-oncogene, making genetic testing essential for at-risk individuals.
Symptoms of Medullary Thyroid Cancer
Symptoms often arise from local tumor growth, metastatic spread, or ectopic hormone production. Early recognition is critical for curative surgery.
1. Neck Lump (Thyroid Nodule)
The most common presentation is a palpable, firm, and non-tender neck mass. Unlike benign nodules, MTC nodules are often fixed to surrounding tissues and may be associated with cervical lymphadenopathy.
2. Cervical Lymphadenopathy
Enlarged lymph nodes in the neck, particularly in the central and lateral compartments, may indicate regional metastasis. Up to 50% of patients have lymph node involvement at diagnosis.
3. Hoarseness or Voice Changes
Invasion of the recurrent laryngeal nerve can cause vocal cord paresis, leading to persistent hoarseness, breathy voice, or dysphonia. This symptom warrants urgent evaluation.
4. Dysphagia or Dyspnea
Large tumors may compress the esophagus or trachea, causing difficulty swallowing (dysphagia) or breathing (dyspnea). These are signs of advanced disease and require immediate medical attention.
5. Chronic Diarrhea
Secretory diarrhea is a hallmark of MTC due to elevated calcitonin and other peptides (e.g., vasoactive intestinal peptide). It is often watery, non-bloody, and may precede the neck mass by months.
6. Elevated Calcitonin and CEA Levels
Although not a symptom, elevated serum calcitonin (>100 pg/mL) and carcinoembryonic antigen (CEA) are highly sensitive biomarkers. Basal calcitonin levels correlate with tumor burden and are used for diagnosis and monitoring.
| Symptom | Description | Clinical Significance |
|---|---|---|
| Neck Lump | Firm, fixed thyroid nodule | Most common; requires FNA biopsy |
| Lymphadenopathy | Enlarged cervical nodes | Indicates regional metastasis |
| Hoarseness | Voice changes due to nerve involvement | Suggests recurrent laryngeal nerve invasion |
| Dysphagia/Dyspnea | Difficulty swallowing or breathing | Advanced local compression |
| Diarrhea | Chronic watery stools | Ectopic hormone secretion; often early sign |
When to See a Doctor
Consult a physician immediately if you experience any of the above symptoms, especially a new neck lump, persistent hoarseness, or unexplained diarrhea. Early detection significantly improves prognosis; the 10-year survival rate for localized MTC exceeds 90%.
Diagnosis and Genetic Testing
Diagnosis involves a combination of biochemical, imaging, and histopathological evaluation. For hereditary MTC, genetic testing is mandatory.
Diagnostic Workup
- Physical Examination: Palpation of thyroid and cervical lymph nodes.
- Blood Tests: Serum calcitonin and CEA levels; elevated basal or stimulated calcitonin is diagnostic.
- Imaging: High-resolution ultrasound, CT, or MRI to assess tumor extent and metastasis.
- Biopsy: Fine-needle aspiration (FNA) with cytology and calcitonin immunostaining.
- Genetic Testing: Next-Generation Sequencing (NGS) of the RET gene to detect germline mutations. Whole Exome Sequencing (WES) may be used for comprehensive analysis in familial cases.
| Test | Purpose | Method |
|---|---|---|
| Calcitonin | Screening and monitoring | Immunoassay |
| CEA | Tumor marker | Immunoassay |
| RET Gene Sequencing | Hereditary MTC detection | NGS (Sanger not used as primary) |
| FNA Biopsy | Cytological confirmation | Ultrasound-guided aspiration |
Treatment Options
- Surgery: Total thyroidectomy with central neck dissection is the primary treatment. Prophylactic thyroidectomy is recommended for asymptomatic RET mutation carriers.
- Radiation Therapy: External beam radiation may be used for residual or recurrent disease.
- Targeted Therapy: Tyrosine kinase inhibitors (e.g., vandetanib, cabozantinib) for advanced or metastatic MTC.
- Systemic Therapy: Chemotherapy is generally ineffective; somatostatin analogs may control diarrhea.
Importance of Early Detection and Genetic Counseling
In India, where awareness is limited, early detection is paramount. Genetic testing for RET mutations enables identification of at-risk family members, allowing prophylactic interventions. DNA Labs India offers comprehensive NGS-based RET testing with rapid turnaround and expert genetic counseling.
Conclusion
Medullary thyroid cancer is a rare but aggressive malignancy. Recognizing symptoms—especially a neck lump, hoarseness, and chronic diarrhea—and pursuing timely diagnostic testing can dramatically improve outcomes. If you or a family member have a history of MEN2 or MTC, consult a specialist and consider genetic testing.
Written by: Dr. Ananya Sharma, MBBS, MD (Internal Medicine)
Medically Reviewed by: Dr. Rajesh Kumar, MD, DM (Medical Genetics)
Last Updated: March 2026